MI Tumor Seek

_______________________________________________________________________________________________________

MI Tumor Seek is a Next-Generation Sequencing (NGS)-based tumor profiling assay that covers DNA mutations, copy number alterations, insertions/deletions, and RNA fusions for select lineages. Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) are also included with every order to inform immunotherapy opportunities.

The information below details the genes tested and segmented by genomic class.

View the full MI Tumor Seek Menu here: MI Tumor Seek Profile Menu

Note:

Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations*, insertions/deletions, genomic signatures (MSI, TMB*) is currently performed for all breast, ovarian, pancreas and prostate cancers. All other tumor types receive 592-gene Next-Generation (DNA) Sequencing.

* Not Available in New York State.
- View 592-gene list: 592 Gene List
The following TAPUR NGS genes are available upon request: EPHA2, FYN, GLI2, LYN, POLD1, MST1R, YES1, and NGS Fusion: Bcrl-abl.

MI Tumor Seek

MI Tumor Seek

View the full MI Tumor Seek Menu here: MI Tumor Seek Profile Menu

Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations*, insertions/deletions, genomic signatures (MSI, TMB*) is currently performed for all breast, ovarian, pancreas and prostate cancers. All other tumor types receive 592-gene Next-Generation (DNA) Sequencing.

* Not Available in New York State.

View 592-gene list: 592 Gene List

The following TAPUR NGS genes are available upon request: EPHA2, FYN, GLI2, LYN, POLD1, MST1R, YES1, and NGS Fusion: Bcrl-abl.

Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations, insertions/deletions, genomic signatures (MSI, TMB) is currently performed for all breast, ovarian, pancreas and prostate cancers. All other tumor types receive 592-gene Next-Generation (DNA) Sequencing.